Verrica Pharmaceuticals Inc
NASDAQ:VRCA

Watchlist Manager
Verrica Pharmaceuticals Inc Logo
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
Watchlist
Price: 0.694 USD 2.66% Market Closed
Market Cap: 62.8m USD
Have any thoughts about
Verrica Pharmaceuticals Inc?
Write Note

Verrica Pharmaceuticals Inc
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Verrica Pharmaceuticals Inc
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
Capital Expenditures
-$303k
CAGR 3-Years
37%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Capital Expenditures
-$4.4B
CAGR 3-Years
-7%
CAGR 5-Years
-4%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Capital Expenditures
-$1.2B
CAGR 3-Years
-9%
CAGR 5-Years
-7%
CAGR 10-Years
-8%
Pfizer Inc
NYSE:PFE
Capital Expenditures
-$3.2B
CAGR 3-Years
-2%
CAGR 5-Years
-4%
CAGR 10-Years
-7%
Merck & Co Inc
NYSE:MRK
Capital Expenditures
-$3.4B
CAGR 3-Years
10%
CAGR 5-Years
-1%
CAGR 10-Years
-11%
Eli Lilly and Co
NYSE:LLY
Capital Expenditures
-$8.3B
CAGR 3-Years
-53%
CAGR 5-Years
-38%
CAGR 10-Years
-18%
No Stocks Found

Verrica Pharmaceuticals Inc
Glance View

Market Cap
62.8m USD
Industry
Pharmaceuticals

Verrica Pharmaceuticals, Inc. engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 38 full-time employees. The company went IPO on 2018-06-15. The firm is focused on developing and commercializing treatments for skin diseases. The firm's lead product candidate, VP-102, is a drug-device combination of its topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. The company is developing VP-102 for the treatment of molluscum contagiosum (molluscum), a highly contagious and primarily pediatric viral skin disease, external genital warts and common warts. The company also intends to develop its second cantharidin-based product candidate, VP-103, for the treatment of plantar warts, which are warts located on the bottom of the foot. The company also intends to develop its third product candidate, LTX-315, for the treatment of dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma.

VRCA Intrinsic Value
1.338 USD
Undervaluation 48%
Intrinsic Value
Price

See Also

What is Verrica Pharmaceuticals Inc's Capital Expenditures?
Capital Expenditures
-303k USD

Based on the financial report for Sep 30, 2024, Verrica Pharmaceuticals Inc's Capital Expenditures amounts to -303k USD.

What is Verrica Pharmaceuticals Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
18%

Over the last year, the Capital Expenditures growth was -52%. The average annual Capital Expenditures growth rates for Verrica Pharmaceuticals Inc have been 37% over the past three years , 18% over the past five years .

Back to Top